Hip & pelvis

  • 제21권3호
  • /
  • Pages.211-218
  • /
  • 2009
  • /
  • 2287-3260(pISSN)
  • /
  • 2287-3279(eISSN)
대한고관절학회 (The Korean Hip Society)
권호 표지

골다공증의 약물 치료

The Medical Treatment of Osteoporosis

  • 임영욱 (가톨릭대학교 의과대학 서울성모병원 정형외과) ;
  • 김용식 (가톨릭대학교 의과대학 서울성모병원 정형외과)
  • Lim, Young-Wook (Department of Orthopedic Surgery, Seoul St. Mary's Hospital, The Catholic University) ;
  • Kim, Yong-Sik (Department of Orthopedic Surgery, Seoul St. Mary's Hospital, The Catholic University)
  • 발행 : 2009.09.30

⟨ 이전 논문 다음 논문 ⟩

초록

이 논문의 목적은 정형외과 의사에게 골다공증을 치료하고 관리하기 위한 치료의 가이드 라인을 제시하기 위함이다. 골다공증을 치료하는 목적은 노인인구에서 골절을 예방하는 것이며 이를 위해서는 칼슘이나 비타민 D 섭취 같은 단순한 약물 치료뿐만 아니라 식생활 개선이나 생활 습관의 변화가 있어야 한다. 정형외과 의사들은 골다공증에 의한 골절환자들을 직접적으로 대하는 사람들이기 때문에, 골다공증에 의한 골절의 예방 및 골다공증의 치료를 적극적으로 하여야 할 의무가 있는 것이다. 이는 의료비용의 절감뿐만 아니라 수명연장 및 삶의 질 향상에도 기여할 수 있을 것이다.

The purpose of this article is to provide orthopaedic surgeons with a guide for the management and treatment of osteoporosis. Preventing fracture prevention is the key efficacy end point in the medical management of osteoporosis for any patient. Enhancement of the bone mass and improving the bone quality are achieved by a combination of lifestyle modification, dietary supplementation with calcium and Vitamin D and pharmacologic treatment. This has proved effective for the prevention and treatment of osteoporosis. The orthopedic surgeon is frequently contacted to identify patients with an osteoporotic fracture. As the orthopaedic surgeon is often the only physician to see a patient who has sustained such a fracture, orthopaedic surgeons must make every effort to determine if the injury is a fragility fracture so that the patient can be treated to prevent future fractures.

키워드

참고문헌

  1. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocriol Metab, 92:911-918, 2007. https://doi.org/10.1210/jc.2006-2207
  2. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med, 355:125-137, 2006. https://doi.org/10.1056/NEJMoa062462
  3. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med, 353:555-565, 2005. https://doi.org/10.1056/NEJMoa050336
  4. Bouxsein ML, Kaufman J, Tosi L, et al. Recommendations for optimal care of the fragility fracture patient to reduce the risk of future fracture. J Am Acad Orthop Surg,12:385-395, 2004.
  5. Karlsson MK, Gerdhem P and Ahlborg HG. The prevention of osteoporotic fractures. J Bone Joint Surg, 87-B:1320-1327, 2005. https://doi.org/10.1302/0301-620X.87B10.16578
  6. Laura Gehrig, Joseph Lane J, O'Connor MI. Osteoporosis: management and treatment strategies for orthopaedic surgeons. J Bone Joint Surg, 90-A:1362-1374, 2008.
  7. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res, 22:1832-1841, 2007. https://doi.org/10.1359/jbmr.070809
  8. Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract, 13:223-229, 2007. https://doi.org/10.1177/1078155207080806
  9. Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract, 13:223-229, 2007. https://doi.org/10.1177/1078155207080806
  10. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des, 9(32): 2643-2658, 2003. https://doi.org/10.2174/1381612033453640
  11. Romas E. Clinical applications of RANK-ligand inhibition. Intern Med J, 39:110-116, 2009. https://doi.org/10.1111/j.1445-5994.2008.01732.x
  12. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297:1465-1477, 2007. https://doi.org/10.1001/jama.297.13.1465
  13. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci, 1117:209-257, 2007. https://doi.org/10.1196/annals.1402.089
  14. Singer AJ and Boonen S. Osteoporosis management: translating research into optimal fracture protection II. Curr Med Res Opin, 24:1789-1796, 2008. https://doi.org/10.1185/03007990802115887
  15. The Korean Society of Bone Metabolism. Diagnosis and Treatment of osteoporosis. 35-88, 2008.
  16. http://www.nof.org/professionals/NOF_CLinicians_ Guide.pdf